Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

作者：Xiuli Tao, Qian Zhang, Pei Yuan, Shuhang Wang, Jianming Ying, Ning Li, Wei Guo, Huijuan Li, Lei Guo, Ying Liu, Zewei Zhang, Shijun Zhao, Shugeng Gao, Ning Wu · 发表于：Translational Lung Cancer Research · 年份：2024 · DOI：10.21037/tlcr-24-598 · 被引用次数：5 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Immune cells in cancer、Cancer Immunotherapy and Biomarkers

Background: Identifying biomarkers to predict responses for neoadjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC) is under intensive study. Considering the interplay between cancer, inflammation, and immunosuppression, we hypothesized that circulating and imaging inflammatory markers could serve as indicators of anti-tumor immune responses, and thus conducting an exploratory study to reveal the predictive value of combining longitudinal systemic inflammatory markers in stratifying pathologic response to neoadjuvant sintilimab. Methods: We retrospectively reviewed 36 patients (29 male and seven female) with NSCLC (stage IA–IIIB) who underwent pre- and post-treatment peripheral blood tests and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scans before and after two cycles of neoadjuvant sintilimab (registration number: ChiCTR-OIC-17013726). The neutrophil-to-lymphocyte ratio (NLR), immune-related adverse events (irAEs) on imaging, and lymphoid organ metabolism [spleen-to-liver ratio (SLR) and bone marrow-to-liver ratio (BLR)] were evaluated to examine their predictive value for the major pathologic response (MPR). Significant variables were used to classify patients into low, intermediate, and high inflammatory burden groups for stratifying pathologic regression and tumor-infiltrating immune cells abundance in the tumor microenvironment. Spearman’s correlation analysis was performed to explore the correlation betwe...